Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .

ClinicalTrials.gov ID

NCT07242300

Lead Sponsor

JHM BioPharma (Tonghua) Co. , Ltd.NETWORK

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

207Estimated

Last Update Posted

Aug 5, 2026Actual

Start Date

Dec 11, 2025Actual

Primary Completion Date

Dec 2026Estimated

Completion Date

Jan 2028Estimated

Official Title

A Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) in Adult Patients With Upper Limb Spasticity

Brief Summary

This is a phase III clinical study to evaluate the efficacy and safety of recombinant botulinum toxin type A（Eveotox）in adult patients with upper limb spasticity. The purpose of this study was to observe efficacy and safety of Eveotox compared with placebo in adult patients with upper limb spasticity.

• Upper Limb Spasticity (ULS)

• Recombinant Botulinum Toxin Type A for injection
• Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Participant must be 18 to 80 years of age inclusive, at the time of signing the informed consent
• Participants with stable post-stroke Spasticity (ULS) for at least 3 months
• Participants with Modified Ashworth Scale (MAS) score of at least 2 at elbow flexor or wrist flexor or finger flexor
• Participants with DAS score of at least 2 on the Principal Target of Treatment (PTT) (one of four functional domains: dressing, hygiene, limb position and pain)
• Participants who have been stable for at least 1 month prior to study entry in terms of oral antispasticity

Exclusion Criteria:

• Previous use of any botulinum toxin within 6 months prior to screening, or plan to use any botulinum toxin during the study.
• History of alcohol or drug abuse.
• Known allergy or hypersensitivity to any component of the study products.
• History of epilepsy
• Known or suspected to be HIV positive, serologically positive for syphilis, or active hepatitis B or C
• Any medical condition that may put the participant at increased risk for botulinum toxin type A use

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

JHM BioPharma (Tonghua) Co. , Ltd.NETWORK

zhangge_cn@hotmail.com

632710985@qq.com

tangjianhua98@126.com

• Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines

  NCT06937944

  RecruitingInterventionalPhase 3Updated Aug 5, 2026
• A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults

  NCT06783114

  RecruitingInterventionalPhase 2Phase 3Updated Jan 22, 2026
• A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity

  NCT07478822

  RecruitingInterventionalPhase 3Updated Apr 2, 2026
• Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke

  NCT01392300

  CompletedInterventionalPhase 3Updated Jan 16, 2017
• Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm

  NCT01603459

  CompletedInterventionalPhase 3Updated Apr 26, 2017
• Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity

  NCT01915459

  CompletedInterventionalPhase 3Updated May 4, 2015